APVO (Aptevo Therapeutics) Moat Score: 3/10 (As of Jun. 27, 2026)


APVO Aptevo Therapeutics Inc APVO
29 GF Score
Price $4.55
! 1 Warning Sign
View Full Analysis

What is Aptevo Therapeutics Moat Score?

Aptevo Therapeutics APVO -0.66% 29 Moat Score is 3 as of Jun. 27, 2026. GuruFocus rates APVO with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 1,404 Biotechnology companies, Aptevo Therapeutics ranks better than 75.5% on this metric.

Aptevo Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Aptevo Therapeutics has No Moat: Aptevo Therapeutics Inc has a limited product portfolio and faces significant competition in the biotech sector. It lacks substantial market share, intellectual property, and regulatory barriers, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Aptevo Therapeutics might have No Moat - Very weak/transient advantages.

Aptevo Therapeutics  (NAS:APVO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Aptevo Therapeutics Moat Score Related Terms

APVO vs FBLG, BGMS, AIM: Moat Score Comparison

For the Biotechnology subindustry, Aptevo Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptevo Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Aptevo Therapeutics's Moat Score falls into.


APVO
29GF Score
Aptevo Therapeutics Inc APVO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Aptevo Therapeutics (APVO) has a Moat Score of 3 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Aptevo Therapeutics ranks #344 out of 1404 companies in the Biotechnology industry, placing it in the top 24.5%.
Is Aptevo Therapeutics' Moat Score too high?
Aptevo Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Aptevo Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Aptevo Therapeutics ranks #344 out of 1404 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aptevo Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aptevo Therapeutics' Moat Score compare to FBLG and BGMS?
According to the Biotechnology industry distribution chart, Aptevo Therapeutics ranks #344 out of 1404 companies for Moat Score. This places Aptevo Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Aptevo Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,404 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aptevo Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptevo Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptevo Therapeutics stock overvalued right now?
Aptevo Therapeutics (APVO) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Aptevo Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Aptevo Therapeutics (APVO), the current Moat Score is 3 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aptevo Therapeutics Business Description

Address 2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
29GF Score

Get the complete analysis for APVO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.55
Price